Number of shares and voting rights of Innate Pharma as at February 10, 2014
Annual results for 2013: Cash position strengthened to €41.3m as at December 31, 2013
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
Innate Pharma announces its financial calendar for 2014 as well as its participation to upcoming investor conferences
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Number of shares and voting rights of Innate Pharma as at December 2, 2013
Innate Pharma raises €20.3 million in a private placement subscribed entirely by US-based specialist investors
Innate Pharma has launched a private placement to raise about 18 millions euros
Innate Pharma initiates IPH43 program to develop «first-in-class» anti-MICA antibody
Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH
